Baxter International (BAX) Q1 results:
Revenues: $2,802M (6.2%); Renal Care: $870M (+2%);
Medication Delivery: $690M (+9%); Pharmaceuticals: $527M (+3%);
Clinical Nutrition: $220M (+7%); Advanced Surgery: $224M (+13%); Acute
Therapies: $156M (+21%); Other: $115M (+7%).
Net Income: $332M (-2.9%); EPS: $0.64 (-3.0%); non-GAAP Net Income: $425M (+7.9%); non-GAAP EPS: $0.82 (+9.3%).
CF Ops: $274M (+104.5%).
Citing COVID-19 uncertainties, the company is not in a position to provide Q2 or FY 2020 guidance at this time.
Shares are up 2% premarket.
Previously: Baxter EPS beats by $0.08, beats on revenue (April 30)
https://seekingalpha.com/news/3566881-baxterplus-2-premarket-on-q1-beat
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.